View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
  2. Company News
June 29, 2018updated 12 Jul 2022 1:14pm

Novartis reports positive interim data from OLE trials of Aimovig

Novartis reported positive results from an interim analysis of two open-label extension studies (OLE) of Aimovig (erenumab) for the treatment of patients with chronic and episodic migraine.

Novartis reported positive results from an interim analysis of two open-label extension studies (OLE) of Aimovig (erenumab) for the treatment of patients with chronic and episodic migraine.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The new findings have supported the established safety and efficacy profile of Aimovig in long-term use for patients with chronic migraine, as well as demonstrated the long-term safety and tolerability of Aimovig in episodic migraine.

The OLE in chronic migraine trial enrolled 609 patients who completed a Phase II, 12-week, double-blind, placebo-controlled parent trial.

Of the enrolled subjects, 451 people completed this study receiving either Aimovig at 70mg or 140mg or changing from 70mg to 140mg throughout the trial.

Out of the total patients, 199 increased their dose from 70mg to 140mg by week 28.

The trial’s primary outcome measure was long-term safety.

Its secondary outcome measure comprised efficacy, as determined by four measures, including change from baseline to week 52 in monthly migraine days (MMD), monthly acute migraine-specific medication days, monthly cumulative hours of headache, and proportion of patients achieving at least a 50% reduction in MMD.

“The trial’s primary outcome measure was long-term safety.”

The most frequent adverse events of the study were viral upper respiratory tract infection, upper respiratory tract infection, sinusitis, arthralgia, and migraine.

In the double-blind treatment phase, the trial did not find any differences in the safety events between Aimovig and placebo.

The OLE in episodic migraine trial included patients completing a Phase II 12-week double-blind, placebo-controlled study of Aimovig in adults with episodic migraine.

Initially, the patients received 70mg of Aimovig monthly. The dose was later increased to 140mg to evaluate the long-term safety of the higher dose.

The trial’s safety and tolerability were analysed by monitoring AEs, electrocardiograms, laboratory assessments, and vital signs.

Of the 383 patients who enrolled in the open-label extension phase, 235 patients remained in the OLE study at the data cut-off date for the interim analysis, all having received Aimovig for at least three years.

The study is expected to be continued for up to five years.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena